UK markets closed

MaxCyte, Inc. (MXCT.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
498.00+25.50 (+5.40%)
At close: 04:03PM BST

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • O
    Offer
    This is the type of biotech investment that now has more than ever a bigger reward than a risk. trading at ~2x their cash and license deals just pile up. with their business model it will look very good in the next year or two. I added today
  • R
    RV
    I bought these to complement my gene editing stocks- and this has taken off today.
  • C
    Christina
    A key challenge in unlocking gene editing (like CRISPR) potential is delivery. MaxCyte is a company that can cheaply, quickly, and reliably deliver gene editors into a lot of cells for ex vivo therapies. You get the upside of cell therapy market growth while diversifying risk across a dozen, potentially hundreds, of therapies.

    I talk more about Maxcyte in this article: https://healthandwealth.substack.com/p/maxcyte-electroporation
    How MaxCyte makes revenue from cell-therapy companies like CRISPR Therapeutics, Editas, and Caribou's R&D expenses
    How MaxCyte makes revenue from cell-therapy companies like CRISPR Therapeutics, Editas, and Caribou's R&D expenses
    healthandwealth.substack.com
  • O
    Offer
    I guess we found our bottom. Today could be big. I am assuming CRSP 110 is using MXCT.
  • S
    Santosh J
    The earnings were terrific. Way above expectations and estimates. What gives on price?
  • O
    Offer
    I assume the news is because of of the Allogene news. They just received a hold on their trial. Looking at MaxCyte investor presentation ALLO is one of their customers. Since ALLO is using MaxCyte for their cell creation it is a double problem
    1) Fear of the unknown. maybe the problem found in the subject has nothing to do with the trial at all but potentially it could be derived by the MaxCyte Cell proccessing.
    2) Even if it is Allo fault AND had nothing to do with MaxCyte, the MaxCyte business model (Which is a great business model) relies on milestones such as phase completion and single digit from the drug revenue. No drug means no revenue.
    I think it is exactly why you should BUY MaxCyte. No matter who the winners and the losers will be, they will use MaxCyte. We never really expected all of the cell theraphy companies to be winners.
  • R
    RV
    Okapi
    @OkapiCapital
    $MXCT with a solid Q2 beating analyst sales estimates by 15%.

    Q2 accelerated to 38% YY and would have been closer to 60% if not for a decline in lumpy program milestones that should accelerate over the coming quarters as partner programs mature.

    Guide looks very conservative.
    4:39 PM · Sep 13, 2021·Twitter for iPhone
  • R
    RV
    What does crbu, beam, ntla , crsp, edit, allo, grph ,dtil ,sgmo sana all have in common?

    Answer: Maxcyte -mxct

    Extrapolated cells- the name in the game for CAR-T and CAR-NK therapy.
  • C
    Cannuck #3
    @RV what do you think of Bio genomics (bngo) and Genprex (GNPX) thank you for your input
  • A
    Abe
    Market cap approaching cash on hand... Guess that could be considered fair value?
  • R
    RV
    Got 590 @ $15.05 today.
  • S
    Santosh J
    Folks. Is the price dump a combo of larger market forces AND the fact that all the insiders in the c-suite sold a bunch of their stake in the past 3 weeks?!? Why the Armageddon?
  • C
    Cannuck #3
    @RV are there any more you are following and are at really early stage?
  • A
    Asian Tiger
    About to cross the rubicon with a US investor base who understand how big cell therapy can be.
  • C
    Cannuck #3
    @RV where do you find them. Is there a place or site where one can look?
  • O
    Offer
    $SANA just signed a license agreement with $BEAM. Should be good for $MXCT as $SANA just recently signed an agreement with MaxCyte for the cells electroporation
  • O
    Offer
    I guess it's just one of the IPOs (Like most) that goes first down to the original IPO price before they take off.
    MXCT was valued in the UK I think about 750M so we are not far. Time to accumulate and then we fly.
    MXCT receives milestone payments based on progress in phases of trials on top of the single-digit from drug revenue so in the next few years we should see explosive growth with all the gene-editing companies working on Cell therapies. GLTA
  • 8
    8989
    What is going on with MXCT? Keeps dropping since I bought it.
  • L
    Liliya
    Highlights of 1q22 call. Strong demand. Added new SPL costumers. Trading at forward 8x EV adj for cash
  • D
    Dan
    Maybe nervous about J Stark Thompson leaving as chairman but he’s 78 and just semi-retiring I suspect. Not a reflection of MaxCyte potential. If I had any more cash I’d buy more now